Searched for
PIRAMAL PHARMA STOCKS
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...- Q4 earnings roundup: Raymond Realty, MCX among 19 companies that delivered 100%+ growth in sales and PATA select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...
- Vedanta demerger: What recent large demergers of Tata Motors, ITC and others tell us about possible listing timeline?Vedanta's mega demerger has created four new entities, with investors eagerly awaiting their stock market listings. Drawing parallels from ...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Vedanta demerger: Do you have the unlisted shares in your demat account? Here’s all you need to knowVedanta's recent demerger has resulted in four new unlisted companies added to shareholders' demat accounts. These entities are expected to...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Vedanta demerger: When will the four new stocks list on NSE, BSE? Here's what investors can expectVedanta’s demerger has left investors awaiting the listing of its four newly carved-out entities, even as the parent stock continues to ris...
- Vedanta demerger: When will the four new stocks list on BSE, NSE? Here’s what recent demergers indicateMining giant Vedanta is set to demerge four businesses into separate listed entities, with May 1 as the record date. Shareholders will rece...
- Should you buy the dip? Strategist Anand James shares his weekly stock strategyMarket expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...
- Market Outlook: Rupak De’s top 3 trading stock picks for the week aheadGeopolitical tensions, rising crude oil, and a weakening rupee are fueling market volatility, according to Rupak De of LKP Securities. He n...
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...
- HDFC Bank, IT majors, and chemical stocks: Where Aditya Shah is hunting for value right nowGlobal markets face uncertainty due to trade tensions and geopolitical issues. Aditya Shah of Hercules Advisors advises investors to study ...
- Pharma, Auto, and IT: Pankaj Pandey shares sectoral insights amid global challengesPankaj Pandey shares insights on Indian sectors facing US tariffs. He sees limited impact on pharma growth but potential benefits for Jubil...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- Piramal Pharma shares in focus after USFDA issues form 483 for Kentucky unitPiramal Pharma's US facility inspection concluded with four observations from the FDA. The company expects a voluntary action indicated cla...
- Stock Radar: 170% rally in a year! Multibagger pharma stock breaks out from 6-week consolidation; time to buy?Piramal Pharma has broken out from a 6-week consolidation on weekly charts, now trading above key moving averages and is positioned to rise...
- Piramal Pharma stock rises over 3%. Here’s whyThe brokerage firm Jefferies assigned buy rating to Piramal Pharma with a target price of Rs 150, implying an upside potential of 20% from ...
- Piramal Pharma shares hit 5% lower circuit after listingEarlier last week, the company obtained a go-ahead from the National Company Law Tribunal (NCLT) for the listing of its equity shares. Furt...
Load More
